论文部分内容阅读
目的:分析晚期乳腺癌患者治疗前后外周血中血管内皮细胞生长因子(VEGF)的变化,探讨VEGF在乳腺癌中的应用价值。方法:采用恩度联合多西紫杉醇及卡培他滨方案(治疗组)及多西紫杉醇联合卡培他滨方案(对照组)治疗晚期乳腺癌55例,ELISA(酶联免疫吸附实验)检测治疗前后外周血VEGF的水平。结果:治疗组临床有效率(RR)为63.3%(19/30),对照组为44.0%(11/25),差异无统计学意义(P>0.05);治疗组临床受益率(CBR)为80.0%(24/30),对照组为56.0%(14/25),差异有统计学意义(P<0.05)。治疗组的患者治疗前后血清VEGF水平显著下降,差异有统计学意义(P<0.01);对照组的患者治疗前后血清VEGF水平下降,但对比差异无统计学意义(P>0.05)。结论:恩度与化疗联合治疗晚期乳腺癌优于单纯化疗,VEGF是一个较好预测乳腺癌疗效的指标。
Objective: To analyze the changes of vascular endothelial growth factor (VEGF) in peripheral blood of patients with advanced breast cancer before and after treatment, and to explore the value of VEGF in breast cancer. Methods: Fifty-five advanced breast cancer patients were treated with Endo combined with docetaxel and capecitabine (the treatment group) and Docetaxel combined with capecitabine (control group), and ELISA (enzyme-linked immunosorbent assay) Peripheral blood VEGF levels before and after. Results: The clinical effective rate (RR) was 63.3% (19/30) in the treatment group and 44.0% (11/25) in the control group, with no significant difference (P> 0.05). The clinical benefit rate (CBR) 80.0% (24/30) in the control group and 56.0% (14/25) in the control group, the difference was statistically significant (P <0.05). The level of serum VEGF in the treatment group decreased significantly before and after treatment (P <0.01). The serum VEGF level in the control group decreased before and after treatment, but the difference was not statistically significant (P> 0.05). Conclusions: Endostar combined with chemotherapy is better than chemotherapy alone in the treatment of advanced breast cancer. VEGF is a good predictor of the efficacy of breast cancer.